Ypsomed Holding AG · SIX:YPSN
Ypsomed — H1 2018/19 Earnings Presentation
33 slides from Ypsomed's earnings presentation, Nov 6, 2018
Slide 1: Half-year figures 2018/19
Half-year figures 2018/19 Zurich, 06 November 2018
Slide 2: Important information
Important information The information contained in this document has not been verified by an independent source. It should be taken with caution and no assurance or guarantee is given (either explicit or implied) with regard to the fairness, accuracy, completeness or correctness of the information o
Slide 3: Focus on own products proves successful
Focus on own products proves successful Ypsomed Diabetes Care Ypsomed Delivery Systems The launch of mylife™ YpsoPump® is Thanks to our innovation strategy, developing successfully above project revenues and order backlog expectations. have continued to grow. The geographic expansion will be
Slide 4: Growth strategy to be pursued
Growth strategy to be pursued Expansion Availability of mylife™ YpsoPump® in 17 countries Market entry mylife™ YpsoPump® in Canada coming soon Approval in the USA on track, US project team has started Innovation Partnership with JDRF for the “Open-Protocol AID Initiative” Introduction of d
Slide 5: Total revenues increased by CHF 45 million
Total revenues increased by CHF 45 million 5 | Ypsomed Holding AG | Half-year figures 2018/19
Slide 6: Sales excluding Omnipod effects grow by 12.6%
Sales excluding Omnipod® effects grow by 12.6% 6 | Ypsomed Holding AG | Half-year figures 2018/19
Slide 7: Growth through own products
Growth through own products In the traditional business Ypsomed Diabetes Care (YDC) grows by 18.1% to CHF 73.2 million. The turnover in the Ypsomed Delivery Systems (YDS) segment increases by 8.6% to CHF 68.1million. 7 | Ypsomed Holding AG | Half-year figures 2018/19
Slide 8: EBIT rises to CHF 68.4 million
EBIT rises to CHF 68.4 million 8 | Ypsomed Holding AG | Half-year figures 2018/19
Slide 9: Investments were more than doubled
Investments were more than doubled Investments increase to CHF 67 million (previous year: CHF 26 million) – CHF 26 million new plant in Schwerin – CHF 23 million expansion of infra- structure and capacities at existing sites – CHF 10 million injection moulding – CHF 8 million further development o
Slide 10: Outlook for the financial year 2018/19
Outlook for the financial year 2018/19 For the full 2018/19 financial year, we expect sales to remain at the same level as the previous year. The final amount of Insulet Corp.'s compensation may differ if existing customers terminate their Omnipod® diabetes therapy within 12 months of contract t
Slide 11: EBIT outlook for the financial year 2018/19
EBIT outlook for the financial year 2018/19 11 | Ypsomed Holding AG | Half-year figures 2018/19
Slide 12: Ypsomed Business Segments
Ypsomed Business Segments 12 | Ypsomed Holding AG | Half-year figures 2018/19
Slide 13: Ypsomed Diabetes Care
Ypsomed Diabetes Care 13 | Ypsomed Holding AG | Half-year figures 2018/19
Slide 14: YDC and mylife Diabetescare focus on the insulin pump market
YDC and mylife™ Diabetescare focus on the insulin pump market for type 1 diabetics Type 1 Diabetics Geographical distribution of current pump users 14 | Ypsomed Holding AG | Half-year figures 2018/19
Slide 15: mylife YpsoPump now available in 17 countries
mylife™ YpsoPump® – now available in 17 countries, approval in Canada expected by end of January 2019 Australia, Austria, Belgium, Czechia, Denmark, Germany, Finland, France, Ireland, Italy, Luxembourg, Netherlands, Poland, Sweden, Switzerland, Spain, UK Bulgaria, Canada, Croatia, India, Israel, Nor
Slide 16: mylife YpsoPump – Market entry USA mid 2019
mylife™ YpsoPump® – Market entry USA mid 2019 FDA approval was submitted at the end of May 2018. The approval is expected unchanged until summer 2019. We are currently recruiting key positions. We then decide on a location, establish the subsidiary and define the strategy for market entry. 1
Slide 17: mylife YpsoPump exceeds expectations
mylife™ YpsoPump® exceeds expectations Our insulin pump system... Easy to learn and use Small, light and discreet Excellent customer service Customer benefit through modularity For every user ... is well received. We therefore expect an installed base of around 10,000 users by the end of t
Slide 18: We repeat our success, but faster
We repeat our success, but faster With mylife™ Diabetescare, we have established ourselves as a trustworthy brand. We have a competitive product. We are represented in more countries than ever. The mylife™ YpsoPump® comes at a very good time. 18 | Ypsomed Holding AG | Half-year figures 2018/
Slide 19: Capacities to be expanded more quickly due to encouraging demand
Capacities to be expanded more quickly due to encouraging demand The capacity for the production of mylife™ YpsoPump® in Burgdorf will be doubled by July 2019. Capacities for the production of the infusion set in Solothurn and Mexico will be continuously increased as of 2019. From Q2 2021, the
Slide 20: Users have very individual needs
Users have very individual needs Pure Pumpers Basic Loopers Full Loopers Advantages of an Advantages of an Advantages of an insulin pump insulin pump in insulin pump in combination with CGM combination with CGM Evtl. use with a FGM Evtl. moderate daily Automatic control interventions No further rest
Slide 21: An insulin pump for all mature users
An insulin pump for all mature users mylife™ YpsoPump® mylife™ YpsoPump® mylife™ YpsoPump® 2.0 2.0 open-protocol + Evtl. use with an + Integration CGM + Integration CGM FGM + Use Open Protocol App 21 | Ypsomed Holding AG | Half-year figures 2018/19
Slide 22: Open platforms for individual therapy solutions
Open platforms for individual therapy solutions mylife™ YpsoPump® 2.0 mylife™ YpsoPump® 2.0 open-protocol We are continuing the digital At the same time, we are working with integration of our portfolio. JDRF to develop an “open-protocol” In the next financial year, we will enabled mylife™ Yps
Slide 23: Sales of pen needles grow by 11%
Sales of pen needles grow by 11% We have a comprehensive core competence in manufacturing of pen needles. We are growing organically 6% above the market. We will sell around 550 million units in the current financial year. We are optimising our existing capacities. New sales opportunities
Slide 24: Ypsomed Delivery Systems
Ypsomed Delivery Systems 24 | Ypsomed Holding AG | Half-year figures 2018/19
Slide 25: Overview of indications and current platforms
Overview of indications and current platforms Indications Indications Diabetes (insulin, GLP-1) Autoimmune disorders Growth disorders (hGH) Migraine Fertility (FSH) Multiple sclerosis Osteoporosis (PTH) Immuno-oncology Parkinson’s Asthma, respiratory diseases Pens Autoinjectors 2
Slide 26: First commercial market launch of YpsoMate
First commercial market launch of YpsoMate® The first active ingredient in an YpsoMate® was launched commercially in October 2018. The active ingredient is a biosimilar from Humira®, the world's best-selling drug for the treatment of autoimmune diseases. Based on our platform, a customer- specif
Slide 27: We are expanding our platforms with new digital services: YDS SmartServices
We are expanding our platforms with new digital services: YDS SmartServices™ 27 | Ypsomed Holding AG | Half-year figures 2018/19
Slide 28: Added value with YDS SmartServices
Added value with YDS SmartServices™ Turnkey services for our Advantages for users pharmaceutical customers Easy integration into existing systems Real-time monitoring of application, and solutions date and success of injections Life cycle management of Extended care beyond the injection geog
Slide 29: Ypsomed Group
Ypsomed Group 29 | Ypsomed Holding AG | Half-year figures 2018/19
Slide 30: Construction work in Schwerin on track
Construction work in Schwerin on track 30 | Ypsomed Holding AG | Half-year figures 2018/19
Slide 31: Construction work at headquarters mostly completed
Construction work at headquarters mostly completed 31 | Ypsomed Holding AG | Half-year figures 2018/19
Slide 32: Important dates
Important dates Presentation of financial figures 2018/19 in Burgdorf 23 May 2019 General assembly of shareholders in Burgdorf 26 June 2019 32 | Ypsomed Holding AG | Half-year figures 2018/19
Slide 33: Questions and answers
Questions and answers